The management of drug-resistant seizures in late 2025 relies on a multi-modal pharmacological approach that integrates traditional anti-epileptic agents with newer, targeted molecules. In Japan, long-term post-marketing studies have demonstrated that stiripentol, when used as an add-on therapy with clobazam and valproate, significantly reduces the frequency of convulsive and myoclonic seizures over multi-year periods. This stabilization is critical for reducing the risk of Sudden Unexpected Death in Epilepsy (SUDEP), which remains a primary concern for the medical community. The Japan Dravet Syndrome Sector highlights that earlier initiation of these specific adjunctive therapies is associated with better neurodevelopmental outcomes and improved tolerability. By maintaining a steady therapeutic level of these medications, clinicians aim to provide a "window of stability" that allows for better engagement in physical and speech therapies, helping to mitigate the cognitive plateau often seen as patients reach school age.

Frequently Asked Questions

Q. What is the goal of "adjunctive" therapy in this condition? A. Because Dravet Syndrome is resistant to standard drugs, adjunctive therapy adds a second or third medication with a different mechanism to achieve better seizure control.

Q. Can these medications cure Dravet Syndrome? A. Currently, medications are symptomatic and aim to reduce seizure frequency and severity rather than correcting the underlying genetic cause.